<DOC>
	<DOCNO>NCT00865436</DOCNO>
	<brief_summary>The purpose study compare relative bioavailability 5 mg Glyburide/500 mg Metformin Hydrochloride Tablets Alpharma 5 mg/500 mg CLUCOVANCE® Tablets Bristol-Myers Squibb Company follow single oral dose ( 1 x 5 mg/500 mg tablet ) healthy adult volunteer administer fasting condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : Randomized , single dose , two-way crossover study fast condition Official Title : A Relative Bioavailability Study 5 mg Glyburide/500 mg Metformin HCl Tablets Under Fasting Conditions Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>1 . Screening Demographics : All volunteer select study healthy men woman 18 year age old time dose . The weight range exceed ± 20 % height body frame per Desirable Weights Adults 1983 Metropolitan Height Weight Table . 2 . Screening Procedures : Each volunteer complete screening process within 28 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system . The screen clinical laboratory procedure include : HEMATOLOGY : hematocrit , hemoglobin , WBC count differential ; RBC count , platelet count ; CLINICAL CHEMISTRY : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase ; HIV antibody hepatitis B surface antigen screen ; URINALYSIS : dipstick , microscopic examination dipstick positive ; . URINE DRUG SCREEN : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiates phencyclidine . SERUM PREGNANCY SCREEN ( female volunteer ) 3 . If female : childbearing potential , practice acceptable barrier method birth control duration study judge investigator ( ) , condom , sponge , foam , jelly , diaphragm ; intrauterine device ( IUD ) , abstinence ; postmenopausal least I year ; surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . 1 . Volunteers recent history drug alcohol addiction abuse . 2 . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined medical investigator ) . 3 . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . 4 . Volunteers demonstrate positive hepatitis B surface antigen screen reactive HIV antibody screen . 5 . Volunteers demonstrate positive drug abuse screen screen study . 6 . Female volunteer demonstrate positive pregnancy screen . 7 . Female volunteer currently breastfeed . 8 . Volunteers history allergic response ( ) glyburide , metformin related drug . 9 . Volunteers history clinically significant allergy include drug allergy . 10 . Volunteers clinically significant illness 4 week prior Period I dose ( determine medical investigator ) . 11 . Volunteers currently use tobacco product . 12 . Volunteers take drug know induce inhibit hepatic• drug metabolism 28 day prior Period I dose . 13 . Volunteers report donate great 150 mL blood within 28 day prior Period I dose . All subject advise donate blood four week complete study . 14 . Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior Period I dose . All subject advise donate plasma four week complete study . 15 . Volunteers report receive investigational drug within 28 day prior Period I dose . 16 . Volunteers report take systemic prescription medication 14 day prior Period I dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Metformin</keyword>
	<keyword>Glyburide</keyword>
	<keyword>Healthy subject</keyword>
</DOC>